Kalaris Therapeutics (KLRS) Net Income by Year
Kalaris Therapeutics, Inc. reported a net loss of $43.4M in fiscal year 2025. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $44.3M net loss. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Kalaris Therapeutics, Inc. has filed alongside them.
Ticker history: ALVR became KLRS (Kalaris Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View ALVR history.
Annual figures, oldest first. Point at a bar to read its period.
KLRS Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
KLRS Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Kalaris Therapeutics, Inc. financials
Frequently Asked Questions
Kalaris Therapeutics, Inc. reported a net loss of $43.4M in fiscal year 2025.
Kalaris Therapeutics, Inc. (KLRS) reported a $44.3M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
Across the 7 fiscal years this page covers, Kalaris Therapeutics, Inc. (KLRS) net income went from -$23.8M in fiscal year 2019 to -$43.4M in fiscal year 2025.
Kalaris Therapeutics, Inc. (KLRS) reported -$11.5M in net income in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Kalaris Therapeutics, Inc. (KLRS) reported on that line in every period on record.